

# IMSURE ACTIVE SURVEILLANCE: ADVERSE EVENT FOLLOWING IMMUNIZATION (AEFI) COVID-19 AMONG SINGLE DOSE VACCINE RECIPIENTS IN MALAYSIA



KEMENTERIAN KESIHATAN MALAYSIA  
Institut Kesihatan Umum

Mohd Amierul Fikri Mahmud<sup>\*1</sup>, Eida Nurhadzira Muhammad<sup>1</sup>, Faizul Akmal Abdul Rahim<sup>1</sup>, Mohd Hatta Abdul Muttalip<sup>1</sup>, Mohd Farihan Md Yatim<sup>1</sup>, Chong Zhuo Lin<sup>1</sup>

<sup>1</sup>Institute for Public Health, National Institutes of Health, Ministry of Health Malaysia.

## Introduction

- Different levels of protection against COVID-19 infection are provided to vaccine recipients through the immunisation programme.
- IMSURE, a surveillance programme launched in collaboration with the Malaysia's COVID-19 National Immunisation Programme, is responsible to monitor the level of immunity and the occurrence of COVID-19 after vaccination.
- This study aims to describe the AEFI among single dose vaccine recipients in Malaysia.

## Results

- The study assessed 562 recipients, and 166 (29.5%) of them reported having AEFI. Most reported AEFI were systemic symptoms (79.5%) such as fever, dizziness and headache, followed by localised symptoms (20.5%) mostly, pain at the injection site.
- No severe AEFI was documented during this study.
- There were significant associations between ethnicity ( $\chi^2 = 13.83$ ,  $p=0.01$ ) and comorbidity ( $\chi^2 = 0.02$ ,  $p=0.02$ ) with AEFI among Convidecia recipients.

## Methodology

- A prospective cohort design was used in this sentinel surveillance study to monitor and follow-up on selected Convidecia vaccine (single-dose vaccine) recipients in Selangor, Sabah and Kedah.
- AEFI was recorded using a questionnaire 14 days after complete dose.
- Descriptive analysis was done to describe the event of AEFI, and the characteristics were compared using the Chi-Square test.

## Discussion & Conclusion

- This finding also in line with NPRA ADR/AEFI report which stated that the majority (93.0%) of reported AEFI were non-serious.
- As conclusion, this study demonstrated that Convidecia vaccine has several mild symptoms of AEFI and suggested that the benefit-to-risk ratio of this vaccine remains favourable.

Sociodemographic & risk factors characteristics among single dose vaccine in Malaysia.

Variables	Experience any AEFI (N=562)				p-value
	Yes	%	No	%	
<b>Sex</b>					
Male	82	49.4	202	51.0	0.727
Female	84	50.6	194	49.0	
<b>Ethnicity</b>					
Malay	54	23.7	174	76.3	<b>0.001</b>
Bumiputera Sabah	20	52.6	18	47.4	
Others	92	31.3	204	68.9	
<b>Age</b>					
18-39	101	29.4	242	70.6	0.972
40-59	58	29.4	139	70.6	
≥ 60	7	31.8	15	68.2	
<b>BMI (WHO 1998)</b>					
Underweight	13	25.0	39	75.0	0.284
Normal	84	33.2	169	66.8	
Overweight	45	28.8	111	71.2	
Obese	24	23.8	77	76.2	
<b>COVID-19 Infection</b>					
Yes	7	25.9	20	74.1	0.429
No	159	29.7	376	70.3	
<b>Comorbidity</b>					
Yes	57	39.9	86	60.1	<b>0.001</b>
No	109	26.0	310	74.0	
<b>Smoking</b>					
Never	91	28.8	225	71.2	0.870
Past	7	33.3	14	66.7	
Current	68	30.2	157	69.8	
<b>Alcohol Use</b>					
Yes	7	36.8	12	63.2	0.454
No	159	29.3	384	70.7	
<b>Stress</b>					
Low	61	25.3	180	74.7	0.710
Moderate	103	32.4	215	67.6	
High	2	66.7	1	33.3	



Data collection activities for Post Vaccination COVID-19 Immunity and Diseases Surveillance in Malaysia (IMSURE) 2021-2022.

## Acknowledgment

The authors would like to thank the Director General of Health Malaysia for his permission to present this poster.